Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study

BACKGROUND: Women with chronic inflammatory diseases face uncertainty regarding the safety of biologics during breast feeding. CRADLE was the first industry-sponsored study to evaluate certolizumab pegol (CZP) concentrations in human breast milk and estimate average daily infant dose (ADID) of mater...

Descripción completa

Detalles Bibliográficos
Autores principales: Clowse, Megan EB, Förger, Frauke, Hwang, Caroline, Thorp, John, Dolhain, Radboud JEM, van Tubergen, Astrid, Shaughnessy, Laura, Simpson, Jeff, Teil, Marie, Toublanc, Nathalie, Wang, Maggie, Hale, Thomas W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705850/
https://www.ncbi.nlm.nih.gov/pubmed/28814432
http://dx.doi.org/10.1136/annrheumdis-2017-211384

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705850/
https://www.ncbi.nlm.nih.gov/pubmed/28814432
http://dx.doi.org/10.1136/annrheumdis-2017-211384

Ejemplares similares